Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking alternatives to various oral or parenteral migraine abortive therapies. Placebo-controlled clinical studies demonstrate that both intranasal forms are effective in relieving migraine headache pain, but published clinical trial information comparing these two intranasal medications with current abortive therapies is lacking. Both agents are generally well tolerated by patients, with the exception of mild, local adverse reactions of the nose and throat. (Am Fam Physician 2000;61:180-6.)
Migraine headaches are fairly common in the general population: 17.6 percent of women and 5.7 percent of men have one or more migraine headaches per year.1 Because of the episodic nature of migraine attacks, treatment options that rapidly and effectively minimize pain are needed. Although nonpharmacologic interventions play a role in headache management, most migraine patients seek relief with medication. Approximately 95 percent of patients with severe migraine take some medication (prescription or over-the-counter) for their headaches.2 A survey of patients with migraine indicated that they desire a medication that provides quick, sustained pain relief and also decreases the likelihood of recurrence.3
Although injectable sumatriptan (Imitrex Statdose) appears to be effective in aborting migraine attacks, many patients are reluctant to self-administer an injection.4-6 Oral medication for the acute treatment of migraine is the most convenient route of administration but is often impractical because of the high association of nausea and vomiting with migraine attacks. Up to 92 percent of patients have experienced nausea during a migraine attack, and 50 to 68 percent also have vomited.3,7 In addition, the absorption of oral medications may be delayed or diminished because of the high prevalence of gastroparesis during the attack.8-10
The recently approved intranasal forms of dihydroergotamine mesylate (Migranal) and sumatriptan (Imitrex) may help alleviate some of the aforementioned problems. The intranasal route of administration is less invasive than self-administration of an injection and offers the advantage of bypassing the need for gastric absorption.
This article reviews these two intranasal forms of migraine medications and their role in the treatment of acute migraine.
Dihydroergotamine Nasal Spray
Dihydroergotamine (DHE) has been used in the parenteral form for the treatment of acute migraine for many years. The intranasal form is labeled by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine headaches.
mechanism of action
DHE is a derivative of ergotamine and exhibits more selective vasoconstriction than the parent compound. It binds to a number of receptor sites in the body, including serotonin, adrenergic and dopaminergic receptors. One postulated mechanism of action is its vasoconstrictive effects on intracranial vessels. Another possible action is inhibition of the release of inflammatory peptide mediators from trigeminal system nerve endings that may be involved in generating migraine pain.11
The mean bioavailability of intranasal DHE is approximately one third that of intravenous DHE. Systemic absorption after intranasal administration varies among patients, depending on different absorption rates and self-administration techniques. On average, maximum plasma concentration is achieved in 45 minutes (range of 30 to 60 minutes). The primary excretory route for DHE is via the bile in the feces, with an average elimination half-life of 10 hours.11
clinical trials: dhe nasal spray vs. placebo
Table 1 reviews the efficacy of DHE nasal spray in comparison with other migraine treatments.11-17 Headache "relief" or "response" in migraine studies is typically defined as a reduction in headache severity (as reported by patients) from moderate or severe to mild or absent pain.
Of the four placebo-controlled trials involving intranasal DHE,11,18-20 only one19 demonstrated a statistically significant difference in response rates between DHE and placebo at the two-hour post-dose period. At four hours post-dose, three of the four trials11,18,19 demonstrated statistically significant effects in favor of the DHE- treated patients. Benefits in the DHE-treated patients were also achieved for the following secondary end points: decrease in severity of nausea,18,19 decrease in rates of photophobia and phonophobia,19 and fewer escape medications needed during the 24-hour post-dose period.19 The number of vomiting episodes did not differ significantly between patients receiving placebo and patients receiving intranasal DHE in any of the studies.
In one study,19 a low incidence of recurrent headache pain within 24 hours after initial response to intranasal DHE was reported; only 14 percent of patients had a recurrence of headache pain after initial response. This low recurrence rate may be due in part to the long half- life of DHE.
During the major clinical trials for intranasal DHE, the most common side effects were related to local reactions of the medication in the nasal passage (rhinitis, application site reactions) and an altered sense of taste. During the study period, 26 of 1,796 patients (1.4 percent) discontinued the active medication because of adverse reactions. The most common reasons for discontinuation were rhinitis, dizziness and facial edema.11
precautions and contraindications
Because of its vasoconstrictive effects, DHE nasal spray should not be taken by patients with known ischemic heart disease or coronary vasospasm. Patients should be evaluated for cardiac risk factors before starting therapy. Other known contraindications include pregnancy (category X) and lactation, uncontrolled hypertension, peripheral arterial obstructive disease, recent history of vascular surgery, severe hepatic or renal disease, ongoing hemiplegic or basilar migraine, and known hypersensitivity to ergot alkaloids. The drug should not be taken within 24 hours of administration of other vasoconstrictive medications such as serotonin agonists, other ergotamine-containing medications or methysergide.
dosage and administration
DHE intranasal spray is currently manufactured and dispensed to patients in a customized administration kit containing four glass ampules per tray. The medication is stored in glass ampules to maintain stability. The glass ampule should be opened and the sprayer device assembled and primed as directed. Each spray is equal to 0.5 mg. Patients should administer one spray into each nostril, wait 15 minutes and repeat the sequence to deliver the total recommended dose of 2 mg. Patients should be instructed not to tilt the head back or inhale through the nose during administration of the medication. Any unused medication in an open ampule should be discarded after eight hours. Safety information regarding the use of more than 3 mg per 24 hours or 4 mg (two doses) per seven days is unavailable.
The manufacturer of DHE nasal spray, Novartis, is in the process of obtaining approval from the FDA for a new type of storage bottle that will not require patients to break the glass ampule.
Sumatriptan Nasal Spray
Sumatriptan has been available in injectable and oral forms in the United States since 1992 and 1995, respectively. The intranasal form of sumatriptan is FDA-labeled for the acute treatment of migraine with or without aura.
mechanism of action
Sumatriptan is a serotonin agonist with primary activity at the vascular 5-HT1 receptor subtype (5-HT1D). The resultant effect of sumatriptan on the serotonin system leads to vasoconstriction and effects on inflammatory peptide release similar to that of DHE.12
The bioavailability for the intranasal route of administration for sumatriptan has been calculated to be 17 percent of that for the subcutaneous route. Sumatriptan reaches maximum plasma concentration in 60 to 90 minutes when administered intranasally. It is metabolized by a monoamine oxidase enzyme system to an inactive compound, with only 3 percent of the parent drug excreted by the kidneys. The average elimination half-life is approximately two hours.12
sumatriptan nasal spray vs. placebo
Table 111-17 summarizes the efficacy data of placebo-controlled trials for sumatriptan nasal spray.12 Headache pain at two hours post-dose decreased significantly in all five clinical trials using the 20-mg dose when compared to placebo.12 In addition, the 5-mg dose had a statistically significant effect in reducing headache pain, compared with placebo in two trials using this dose.12 In both of these trials, however, the patients receiving the 20-mg dose achieved better headache relief than patients receiving the 5-mg dose
(P <0.05). The sumatriptan-treated patients also had a lower incidence of migraine-associated symptoms (such as nausea, vomiting, phonophobia and photophobia), when compared with the placebo-treated patients.21,22
The intranasal form of sumatriptan is generally well tolerated, with mild, local reactions reported as the most common events during the clinical trials. One of the most frequently reported complaints was the bitter taste of the medication. In the placebo-controlled trials, nearly 25 percent of patients complained about the bitter taste when using the 20-mg spray (versus 1.7 percent of placebo-treated patients). Of the 3,653 clinical trial patients, 0.4 percent withdrew because of adverse reactions.12
precautions and contraindications
Because of its vasoconstrictive properties, sumatriptan should be avoided in patients with known coronary artery disease or Prinzmetal's variant angina. Patients at risk for coronary artery disease should undergo a cardiac evaluation before taking the product. When therapy is initiated in this high-risk group, the first dose should be administered in a physician's office to allow assessment for possible adverse outcomes.
Intranasal sumatriptan should not be taken within 24 hours of other ergotamines or ergotamine-like drugs. Patients currently taking monoamine oxidase inhibitors (MAOIs) should avoid the use of sumatriptan. A two-week washout period should elapse between discontinuation of the MAOI and initiation of sumatriptan. It is also contraindicated in patients with hemiplegic or basilar migraine, uncontrolled hypertension or history of allergic reactions to sumatriptan or its components.
Sumatriptan is listed as a pregnancy category C medication. If sumatriptan is prescribed during pregnancy, health professionals should contact the Glaxo Pregnancy Registry to track the outcomes (telephone: 800-336-2176).
dosage and administration
Sumatriptan is available in 5-mg and 20-mg, single-use, preprimed spray devices. Patients should be instructed to administer one spray into one nostril. If a rescue dosage is required, patients should wait at least two hours before administering another. The total dosage of sumatriptan administered per
24 hours should not exceed 40 mg.
Because the 20-mg strength fared better in clinical trials, it is generally recommended that treatment be initiated at this strength. The 5-mg strength may be prescribed for those patients who may be more sensitive to the medication's effects and who are likely to experience more adverse reactions with the higher dose.
intranasal route vs. oral or injectable routes
It is difficult to directly compare these new intranasal medications with the current abortive regimens in terms of overall efficacy. The efficacy data provided in Tables 111-17 and 24,19,21-26 (headache response rates and headache recurrence rates) are derived from results of clinical trials. In general, trial data comparing abortive agents is lacking; therefore, additional published data are needed to assess the most effective treatment for acute migraine.
For physicians, new abortive medications and routes of administration have allowed more patients to be effectively treated. The range of options may seem wide but can be narrowed by tailoring the medication to each patient based on the migraine pattern, previous responses to medications and individual preferences. A thorough review of all the available abortive medications is not included here, but a previous manuscript has addressed prescribing information for most of the available abortive regimens.27
The intranasal forms of migraine medications are reasonable options for patients with acute migraine. The relatively quick absorption into the bloodstream enables a rapid headache response. Patient acceptance for this route of administration, in comparison with other routes, will need to be addressed when selecting which treatment to use. Patients who have migraine attacks of variable severity may prefer to have two or three dosage forms available for personal use, depending on the rate of pain escalation, associated symptoms and whether or not they are at home.
The costs of the newer drugs (Table 311-17) may be a factor in the selection of an appropriate dosage form. Injectable sumatriptan is the most expensive form of triptan currently available. The acquisition costs for intranasal sumatriptan and DHE are comparable. Although many insurance companies are limiting access to these newer migraine medications, pharmacoeconomic studies may reveal overall cost- effectiveness.28
When comparing sumatriptan nasal spray with DHE nasal spray, some factors should be considered. The sumatriptan device is less cumbersome to use than the DHE nasal spray. Once the new sprayer formulation for DHE is FDA-labeled for this indication, this advantage will no longer be of major importance. An advantage of the DHE nasal spray is the longer serum half-life, resulting in fewer recurrent headaches than with sumatriptan.
The authors thank Susan Boyer and Norman Paradise, Ph.D., for assistance in preparation of the manuscript.
1.Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-9.
2.Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993;43(6 suppl 3):S6-10.
3.Silberstein SD. Migraine symptoms: results of a survey of self- reported migraineurs. Headache 1995; 35:387-96.
4.The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21.
5.Cady RK, Dexter J, Sargent JD, Markley H, Osterhaus JT, Webster CJ. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993;43:1363-8 [Published erratum in Neurology 1993;43:2010].
6.Akpunonu BE, Mutgi AB, Federman DJ, Volinsky FG, Brickman K, Davis RL, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med 1995;25:464-9 [Published erratum in Ann Emerg Med 1995;25:857].
7.Rasmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia 1991;11:129-34.
8.Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984;4:107-11.
9.Volans GN. Migraine and drug absorption. Clin Pharmacokinet 1978;3:313-8.
10.Volans GN. Absorption of effervescent aspirin during migraine. Br Med J 1974;4:265-8.
11.Package Insert. Dihydroergotamine mesylate nasal spray (Migranal). East Hanover, N.J.: Novartis Pharmaceuticals Co., 1997.
12.Package Insert. Sumatriptan Nasal Spray (Imitrex). Research Triangle Park, N.C.: Glaxo Wellcome, Inc., 1997.
13.Package insert. Sumatriptan succinate tablets (Imitrex). Research Triangle Park, N.C.: Glaxo Wellcome, Inc., 1998.
14.Package insert. Sumatriptan succinate injection (Imitrex). Research Triangle Park, N.C.: Glaxo Wellcome, Inc., 1997.
15.Package insert. Naratriptan hydrochloride (Amerge) tablets. Research Triangle Park, N.C.: Glaxo Wellcome, Inc., 1998.
16.Package insert. Rizatriptan (Maxalt) tablets. West Point, Pa: Merck & Co., Inc., 1998.
17.Package insert. Zolmitriptan (Zomig) tablets. Wilmington, Delaware: Zeneca Pharmaceuticals, 1997.
18.Ziegler D, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44(3 pt 1):447-53.
19.Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996;53:1285- 91.
20.The Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache 1995;35:177- 84.
21.Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 1997;49:1225-30.
22.Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 1998;7:234-40.
23.Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrence. Cephalagia 1994; 14:330-8.
24.Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. The Naratriptan S2WA3001 Study Group. Headache 1997;37:640-5.
25.Matthew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 1997;49:1485-90.
26.Rapoport AM, Ramadan NM, Adelman JU, Matthew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo- controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997;49:1210-8.
27.Moore KL, Noble SL. Drug treatment of migraine: Part I. Acute therapy and drug-rebound headache. Am Fam Physician 1997;56:2039- 48,2051-4.
28.Schweitzer SO. The economics of migraine (Presentation). Am J Manag Care 1999;5(2 suppl):S91-8.
Richard W. Sloan, m.d., r.ph., coordinator of this series, is chairman and residency program director of the Department of Family Medicine at York (Pa.) Hospital and clinical associate professor in family and community medicine at the Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pa.
CRAIG D. LOGEMANN, Pharm.D., is an assistant clinical professor at the University of Iowa College of Pharmacy, Iowa City, and is part of the clinical faculty of the Iowa Lutheran Hospital Family Practice Residency in Des Moines. He received his doctor in pharmacy degree from the University of Minnesota College of Pharmacy, Minneapolis.
LYNN M. RANKIN, M.D., is a clinical neurologist at Integra Health Medical Foundation, Des Moines, Iowa. Dr. Rankin received her medical degree from the University of Iowa College of Medicine, Iowa City, and completed residency training in internal medicine at the University of Arizona Affiliated Hospitals, Tucson. She specializes in headache treatment.
Address correspondence to Craig D. Logemann, Pharm.D., 840 East University Avenue, Des Moines, IA 50316-2396. Reprints are not available from the authors.
COPYRIGHT 2000 American Academy of Family Physicians
COPYRIGHT 2000 Gale Group